I work in the Policy and Campaigns Team at Breast Cancer Care and I wanted to ask if anyone is, or has been, on the clinical trial for abemaciclib?
Abemaciclib is currently being considered by the Scottish Medicines Consortium (SMC) to be made available on the NHS in Scotland for treating hormone-receptor positive, HER2 negative secondary breast cancer. If approved its use will offer those who have previously been treated with hormone therapy for their secondary breast cancer the opportunity to benefit from this drug.
We are gathering evidence to contribute to SMC’s patient carer groups submissions and we want to hear from you. We will use the experiences of women who are on the clinical trial for abemacicilb to help us inform our response on what access to this drug would mean to women with hormone-receptor positive, HER2 negative breast cancer.